UCB Pharma

vorige Seite Seite 1 von 2 nächste Seite

UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's …

OTE0003
10.10.2019 09:38
 

Experts Consider Osteoporosis to Be a Silent Epidemic Which Is Neglected and Under Addressed, According to New Survey Released Today

A new European survey, released today by UCB, reveals that bone specialists believe osteoporosis and fragility fractures are neglected and under prioritized by their healthcare systems, and action needs to …

OTE0006
20.09.2019 17:10
 

UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

* Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints

OTE0001
18.10.2018 07:01
 

UCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease

* NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without levodopa) or in combination with levodopa

OTE0008
02.07.2018 18:31
 

New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018)

Serves Key Patient Populations Including, Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic, Inflammatory Diseases

OTE0003
07.06.2018 09:17
 

UCB Joins with ILAE and IBE to Encourage World Health Assembly Members to Continue Recognition of Epilepsy as Global Health Priority

Representatives from the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE), alongside prominent members of the Global epilepsy community, are meeting this week to …

OTE0001
22.05.2018 07:03
 

UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients

- BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures

OTE0001
14.05.2018 07:02
 

UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

UCB today announced an agreement to acquire the rights to Proximagen's Midazolam Nasal Spray (USL261)[1], an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures …

OTE0001
20.04.2018 07:02
 

UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off

UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA).

OTE0001
05.04.2018 07:02
 

UCB's bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis

UCB today presented results from a Phase 1B study evaluating pharmacokinetics, safety, tolerability and preliminary efficacy of multiple doses of bimekizumab in patients with psoriatic arthritis (PsA) who …

OTE0001
10.06.2016 08:34
 

Final Call for Entries to the 2010 Excellence in Epilepsy Journalism Award

The Excellence in Epilepsy Journalism Award, a joint initiative of the International Bureau for Epilepsy (IBE) and UCB, recognizes and rewards journalists from across the world who produce informed and …

OTE0001
13.09.2010 09:17
 

"Excellence in Epilepsy Journalism Award"

Das Internationale Büro für Epilepsie (IBE) hat heute gemeinsam mit UCB den Preis "Excellence in Epilepsy Journalism Award 2010" ausgeschrieben.

OTS0004
27.04.2010 07:02
 
vorige Seite nächste Seite